Esther Ollig

  • Citations Per Year
Learn More
AIMS To carry out an immunohistochemical study on bone marrow (BM) biopsy specimens in 75 patients with chronic myelogenous leukaemia (CML) on long-term STI571 therapy. METHODS AND RESULTS Sequential BM specimens taken at intervals of 21 +/- 6 months were investigated by enzyme- and immunohistochemistry including proliferating cell nuclear antigen and(More)
Following therapy with imatinib (STI571) hematologic and cytogenetic response in chronic myeloid leukemia (CML) is associated with conspicuous alterations of bone marrow (BM) morphology. Besides reduction of cellularity and fibrosis, small megakaryocytes characteristic for this disorder were replaced by large, normally appearing cells of this lineage.(More)
Bei der CML kommt es nach Therapie mit Imatinib (STI571) zu auffallenden Veränderungen der Knochenmarkmorphologie. Bisher ist nicht bekannt, in welchem Ausmaß diese mit einem Verlust der bcr/abl-Translokation einhergehen. Um die therapiebedingte Regression der leukämischen Zellpopulation abzuklären, wurden 14 Patienten ausgewählt, die keinerlei(More)
In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14(More)
  • 1